BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...of the immune system (see "Target Wide, Test Narrow in Lupus" ). Tradjenta non-inferior to glimepiride...
...Germany) and Eli Lilly and Co. (NYSE:LLY) said DPP-4 inhibitor Tradjenta linagliptin was non-inferior to glimepiride...
...receiving Tradjenta experienced CV death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE) vs. 12% for glimepiride...
BioCentury | Apr 10, 2019
Clinical News

Aetion, Brigham and Women's partnerships will inform FDA RWE standards

...of the CAROLINA cardiovascular outcomes trial. CAROLINA is a non-inferiority trial of Tradjenta linagliptin vs. glimepiride...
BioCentury | Aug 3, 2018
Clinical News

Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

...second CV outcomes trial this year: the Phase III CAROLINA trial comparing Tradjenta to Amaryl glimepiride...
...to develop and commercialize Tradjenta and other diabetes candidates under a 2011 deal. Tradjenta and Amaryl...
BioCentury | Feb 9, 2018
Company News

Intarcia terminates late-stage diabetes trials

...was also not disclosed. The terminated Phase IIIb trial compared ITCA 650 to empagliflozin or glimepiride...
BioCentury | Feb 2, 2018
Company News

Intarcia terminates Phase III diabetes trials

...regarding steps moving forward. The terminated Phase IIIb trial compared ITCA 650 to empagliflozin or glimepiride...
BioCentury | Jan 4, 2016
Clinical News

Avandia rosiglitazone regulatory update

...REMS, removing the prescribing and dispensing restrictions. Affected products also include Avandamet rosiglitazone/metformin and Avandaryl rosiglitazone/glimepiride...
BioCentury | Jun 8, 2015
Company News

GlaxoSmithKline sales and marketing update

...has a “hint of a minor added benefit” in patients with Type II diabetes vs. glimepiride...
...the Tanzeum arm experienced fewer non-serious/non-severe adverse events but noted that Tanzeum is injected while glimepiride...
BioCentury | Jun 23, 2014
Clinical News

Dulaglutide: Additional Phase III data

...the open-label, international Phase III AWARD-2 trial in 807 Type II diabetics on metformin and glimepiride...
BioCentury | Mar 27, 2014
Distillery Therapeutics

Indication: Pulmonary disease

...to treat dyslipidemia and hypertriglyceridemia. GlaxoSmithKline plc markets the PPARg agonists Avandamet rosiglitazone/metformin and Avandaryl rosiglitazone/glimepiride...
BioCentury | Feb 3, 2014
Clinical News

Ertugliflozin: Phase III started

...compare 5 and 15 mg oral ertugliflozin once daily plus metformin for 2 years vs. glimepiride...
Items per page:
1 - 10 of 109